Profile data is unavailable for this security.
About the company
Halozyme Therapeutics, Inc. is a biopharmaceutical company advancing solutions to improve patient experiences and outcomes for emerging and established therapies. The Company's commercially-validated solution, ENHANZE drug delivery technology with the proprietary enzyme rHuPH20, is used to facilitate the subcutaneous delivery of injected drugs and fluids, with a focus on improving the patient experience with rapid subcutaneous delivery and reduced treatment burden. The Company licenses its technology to biopharmaceutical companies to collaboratively develop products that combine ENHANZE with its partners’ proprietary compounds. It also develops, manufactures and commercializes, for itself or with partners, drug-device combination products using its advanced auto-injector technologies. The Company has two commercial proprietary products, Hylenex and XYOSTED. It also has a proprietary ultra-high concentration microparticle formulation technology for biologics, branded Hypercon.
- Revenue in USD (TTM)1.24bn
- Net income in USD595.49m
- Incorporated2007
- Employees350.00
- LocationHalozyme Therapeutics Inc12390 EL CAMINO REALSAN DIEGO 92130United StatesUSA
- Phone+1 (858) 794-8889
- Fax+1 (302) 655-5049
- Websitehttps://www.halozyme.com/
More ▼
Mergers & acquisitions
| Acquired company | HALO:NSQ since announced | Transaction value |
|---|---|---|
| Surf Bio Inc | 17.34% | 400.00m |
| Elektrofi Inc | 8.32% | 900.00m |
Data delayed at least 15 minutes, as of Feb 13 2026 21:00 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mirum Pharmaceuticals Inc | 471.79m | -41.42m | 5.33bn | 355.00 | -- | 18.12 | -- | 11.29 | -0.8613 | -0.8613 | 9.26 | 5.69 | 0.6494 | 4.15 | 5.37 | 1,465,199.00 | -5.70 | -29.54 | -7.04 | -34.57 | 79.92 | -- | -8.78 | -92.71 | 3.16 | -22.48 | 0.5144 | -- | 80.76 | -- | 46.18 | -- | 136.96 | -- |
| PTC Therapeutics, Inc. | 1.78bn | 751.72m | 5.58bn | 939.00 | 8.14 | -- | 7.11 | 3.13 | 8.53 | 8.53 | 21.64 | -1.95 | 0.7932 | 1.28 | 8.83 | 1,894,728.00 | 33.51 | -26.68 | 49.97 | -34.84 | 96.83 | 93.49 | 42.25 | -74.67 | 2.26 | 6.03 | 1.07 | -- | -13.97 | 21.32 | 42.02 | -- | -13.92 | -- |
| Rhythm Pharmaceuticals Inc | 174.33m | -197.71m | 6.54bn | 283.00 | -- | 43.94 | -- | 37.54 | -3.10 | -3.10 | 2.74 | 4.43 | 0.4006 | 1.03 | 6.66 | 616,021.20 | -44.19 | -52.46 | -57.53 | -61.22 | 89.40 | -- | -110.32 | -354.18 | 4.53 | -27.83 | 0.2693 | -- | 68.06 | -- | -43.26 | -- | -- | -- |
| Krystal Biotech Inc | 373.16m | 198.91m | 8.02bn | 275.00 | 41.49 | 7.04 | 39.21 | 21.48 | 6.66 | 6.66 | 12.50 | 39.26 | 0.3358 | 0.7616 | 3.29 | 1,356,960.00 | 17.90 | -4.81 | 19.49 | -5.07 | 94.26 | -- | 53.30 | -41.51 | 9.73 | -- | 0.00 | -- | 473.02 | -- | 715.58 | -- | -7.91 | -- |
| Axsome Therapeutics Inc | 561.26m | -229.53m | 9.14bn | 683.00 | -- | 123.65 | -- | 16.28 | -4.67 | -4.67 | 11.40 | 1.47 | 0.9121 | 2.40 | 3.50 | 821,761.40 | -37.30 | -59.62 | -68.09 | -80.32 | 91.86 | -- | -40.89 | -134.06 | 1.50 | -28.27 | 0.7255 | -- | 42.53 | -- | -20.05 | -- | 75.71 | -- |
| Halozyme Therapeutics, Inc. | 1.24bn | 595.49m | 9.34bn | 350.00 | 16.70 | 18.53 | 13.79 | 7.52 | 4.76 | 4.76 | 9.90 | 4.29 | 0.5728 | 1.21 | 3.93 | 3,551,006.00 | 27.45 | 22.20 | 35.10 | 25.70 | 84.55 | 80.85 | 47.91 | 45.39 | 1.37 | -- | 0.7499 | 0.00 | 22.44 | 38.95 | 57.71 | -- | 21.50 | -- |
| Jazz Pharmaceuticals PLC | 4.16bn | -368.48m | 10.11bn | 2.80k | -- | 2.55 | 31.80 | 2.43 | -6.07 | -6.07 | 67.81 | 65.18 | 0.3522 | 0.936 | 5.59 | 1,484,940.00 | -3.12 | 1.36 | -3.62 | 1.50 | 88.49 | 88.18 | -8.85 | 3.98 | 1.44 | 2.17 | 0.5752 | 0.00 | 6.12 | 13.48 | 35.02 | 1.37 | -23.40 | -- |
| Avidity Biosciences Inc | 20.87m | -549.79m | 11.28bn | 391.00 | -- | 5.67 | -- | 540.34 | -4.17 | -4.17 | 0.1589 | 12.85 | 0.0111 | -- | 2.78 | 53,370.84 | -29.13 | -30.46 | -31.29 | -33.14 | -- | -- | -2,634.59 | -1,901.74 | -- | -- | 0.00 | -- | 13.99 | 36.27 | -51.87 | -- | 97.52 | -- |
| Biomarin Pharmaceutical Inc | 3.09bn | 520.42m | 11.50bn | 3.04k | 22.44 | 1.90 | 19.07 | 3.72 | 2.67 | 2.67 | 15.82 | 31.53 | 0.4278 | 0.4512 | 3.95 | 1,017,764.00 | 7.20 | 2.18 | 8.04 | 2.46 | 81.32 | 76.43 | 16.82 | 6.07 | 3.10 | -- | 0.0897 | 0.00 | 17.97 | 10.86 | 154.62 | -- | -9.83 | -- |
| Neurocrine Biosciences Inc | 2.86bn | 478.60m | 12.46bn | 2.00k | 26.62 | 3.82 | 24.49 | 4.35 | 4.66 | 4.66 | 27.91 | 32.50 | 0.6851 | 0.8244 | 4.91 | 1,430,250.00 | 11.46 | 9.00 | 13.48 | 10.78 | 98.18 | 98.32 | 16.73 | 13.51 | 3.30 | -- | 0.00 | -- | 21.45 | 22.29 | 40.23 | 3.28 | 25.55 | -- |
| Elanco Animal Health Inc | 4.59bn | 36.00m | 12.49bn | 9.00k | 350.88 | 1.85 | 17.69 | 2.72 | 0.0716 | 0.0716 | 9.23 | 13.58 | 0.3422 | 1.24 | 5.30 | 510,111.10 | 0.2683 | -2.71 | 0.2993 | -3.02 | 54.96 | 54.72 | 0.7841 | -9.52 | 1.23 | 1.30 | 0.3735 | -- | 0.4981 | 7.65 | 127.46 | 37.85 | -3.99 | -- |
Data as of Feb 13 2026. Currency figures normalised to Halozyme Therapeutics Inc's reporting currency: US Dollar USD
37.21%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| BlackRock Fund Advisorsas of 31 Dec 2025 | 11.54m | 9.81% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 10.65m | 9.06% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 5.12m | 4.36% |
| Arrowstreet Capital LPas of 31 Dec 2025 | 3.22m | 2.74% |
| D. E. Shaw & Co. LPas of 30 Sep 2025 | 2.65m | 2.25% |
| Geode Capital Management LLCas of 31 Dec 2025 | 2.43m | 2.07% |
| Snyder Capital Management LPas of 31 Dec 2025 | 2.40m | 2.04% |
| Dimensional Fund Advisors LPas of 31 Dec 2025 | 1.93m | 1.64% |
| AllianceBernstein LPas of 30 Sep 2025 | 1.91m | 1.62% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 1.90m | 1.62% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
